Insys Therapeutics, Inc.
INSY
INSY was delisted on the 18th of June, 2019.
113 hedge funds and large institutions have $585M invested in Insys Therapeutics, Inc. in 2014 Q4 according to their latest regulatory filings, with 27 funds opening new positions, 39 increasing their positions, 34 reducing their positions, and 21 closing their positions.
95% more call options, than puts
Call options by funds: $9.01M | Put options by funds: $4.63M
29% more first-time investments, than exits
New positions opened: 27 | Existing positions closed: 21
15% more repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 34
8% more capital invested
Capital invested by funds: $539M → $585M (+$45.8M)
2% more funds holding
Funds holding: 111 → 113 (+2)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
+$20.1M |
| 2 |
JHIU
Janus Henderson Investors US
Denver,
Colorado
|
+$11.3M |
| 3 |
FCM
Frontier Capital Management
Boston,
Massachusetts
|
+$9.31M |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
+$9.11M |
| 5 |
Morgan Stanley
New York
|
+$9.06M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ECP
Empyrean Capital Partners
Los Angeles,
California
|
-$22.1M |
| 2 |
BTP
Bloom Tree Partners
New York
|
-$20.7M |
| 3 |
Tiger Global Management
New York
|
-$11.6M |
| 4 |
FAM
Foundation Asset Management
White Plains,
New York
|
-$9.12M |
| 5 |
Millennium Management
New York
|
-$5.99M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
CAM
126
ClariVest Asset Management
San Diego,
California
| – | -$93K | -4,800 | Closed |
|
|
CCM
127
Cupps Capital Management
Chicago,
Illinois
| – | -$87K | -4,490 | Closed |
|
|
BJ
128
BlackRock Japan
Tokyo,
Japan
| – | -$59K | -3,042 | Closed |
|
129
BNP Paribas Financial Markets
Paris,
France
| – | -$22.5K | -1,158 | Closed |
|
|
VIA
130
Vantage Investment Advisors
State College,
Pennsylvania
| – | -$19K | -1,000 | Closed |
|
|
TDC
131
Thompson Davis & Co
Richmond,
Virginia
| – | -$10K | -500 | Closed |
|
132
US Bancorp
Minneapolis,
Minnesota
| – | -$10K | -500 | Closed |
|
|
PFG
133
Piershale Financial Group
Barrington,
Illinois
| – | -$3K | -150 | Closed |
|
134
Ameriprise
Minneapolis,
Minnesota
| – | -$1K | -30 | Closed |
|
INSY Hedge Fund Activity: Q4 2014 in Review
113 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in Insys Therapeutics, Inc. (INSY) for Q4 2014, worth a combined $585M — up 8.5% from $539M a quarter earlier.
Buyers outnumbered sellers: 27 funds opened new INSY positions and 21 closed out — a net gain of 6 holders — while 39 added to existing stakes and 34 trimmed.
The largest buyer was OrbiMed, adding an estimated $20.1M. The largest seller was Empyrean Capital Partners, cutting an estimated $22.1M.
- 113 institutional investors held Insys Therapeutics, Inc. (INSY) as of Q4 2014, up from 111 in Q3 2014.
- Funds reported $585M of Insys Therapeutics, Inc. stock for Q4 2014, up 8.5% quarter-over-quarter.
- 27 funds opened new Insys Therapeutics, Inc. positions in Q4 2014 and 21 closed out, a net change of +6 holders.
- The largest Insys Therapeutics, Inc. buyer in Q4 2014 was OrbiMed, an estimated $20.1M added.
- The largest Insys Therapeutics, Inc. seller in Q4 2014 was Empyrean Capital Partners, an estimated $22.1M sold.
Based on aggregated 13F filings for Q4 2014.